Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function
Authors:
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 175, 61-67
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and ApixabanCanadian Journal of Cardiology, 2013
- Monitoring plasma levels of factor Xa inhibitors: how, why and when?Expert Review of Hematology, 2013
- Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisJournal of Thrombosis and Haemostasis, 2013
- Oral Anticoagulant TherapyChest, 2012
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThrombosis and Haemostasis, 2010
- DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJournal of Thrombosis and Haemostasis, 2008
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007